Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients.

Lee-Ann Tjon-Kon-FatMarie LundholmMona SchröderThomas WurdingerCamilla Thellenberg-KarlssonAnders WidmarkPernilla Wikström Rolf Jonas Andreas Nilsson

Published in: The Prostate (2017)

Analyzing tumor-derived biomarkers in platelets of CRPC patients enabled prediction of the outcome after abiraterone therapy with higher accuracy than baseline serum PSA or PSA response.

Keyphrases

prostate cancer
end stage renal disease
ejection fraction
newly diagnosed
radical prostatectomy
prognostic factors
peritoneal dialysis
stem cells
mesenchymal stem cells